Viamet Pharmaceuticals Initiates Phase 1/2 Clinical Trial of Novel Prostate Cancer Therapy, VT-464
Published: Jan 04, 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer (CRPC). VT-464 is a novel, non-steroidal, small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology. In preclinical models VT-464 preferentially inhibits the lyase reaction of the CYP17 enzyme over the hydroxylase reaction, which differentiates it from approved agents such as abiraterone acetate.